High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance

References

• Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc 2007;82:441–7.
   PubMed Web of Science ®Google Scholar
• Teixeira A, Cherin P, Demoule A, et al. Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies. Neuromuscul Disord 2005;15:32–9.
   PubMed Web of Science ®Google Scholar
• Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 2002;41:7–13.
   PubMed Web of Science ®Google Scholar
• Mastaglia FL, Garlepp MJ, Phillips BA, et al.Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003;27:407–25.
   PubMed Web of Science ®Google Scholar
• Marie I. Therapy of polymyositis and dermatomyositis. Presse Med 2011;40:e257–70.
   PubMedGoogle Scholar
• Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013;88:83–105.
   PubMed Web of Science ®Google Scholar
• Roifman CM, Schaffer FM, Wachsmuth SE, et al. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987;258:513–5.
   PubMed Web of Science ®Google Scholar
• European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2005;10:220–8.
   PubMed Web of Science ®Google Scholar
• Dimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. Neurol Clin 2014;32:595–628.
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314–24.
   PubMed Web of Science ®Google Scholar
• Guimaraes-Costa R, Iancu Ferfoglia R, Viala K, et al. Challenges in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Rev Neurol (Paris) 2014;170:595–601.
   PubMed Web of Science ®Google Scholar
• European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society–First Revision. J Peripher Nerv Syst 2010;15:1–9.
   Web of Science ®Google Scholar
• Koller H, Kieseier BC, Jander S, et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343–56.
   PubMed Web of Science ®Google Scholar
• Recommendations on diagnostic strategies for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2008;79:115–8.
   PubMed Web of Science ®Google Scholar
• Leger JM, Vargas S, Lievens I. Efficacy of intravenous immunoglobulin in multifocal motor neuropathy. Ann NY Acad Sci 2007;1110:248–55.
   PubMed Web of Science ®Google Scholar
• Stojkovic T, Dubucquoi S. [The use of intravenous immunoglobulins in neurology]. Rev Neurol (Paris) 2005;161:781–94. La place des immunoglobulines intraveineuses en neurologie.
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Hara M, Koike T, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol 2012;22:382–93.
   PubMed Web of Science ®Google Scholar
• Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994;44:429–32.
   PubMed Web of Science ®Google Scholar
• Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248–52.
   PubMed Web of Science ®Google Scholar
• Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256–62.
   PubMed Web of Science ®Google Scholar
• Leger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124:145–53.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials. Neurol Sci 2003;24 Suppl 4:S256–9.
   PubMed Web of Science ®Google Scholar
• van Schaik IN, van den Berg LH, de Haan R, et al. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005: CD004429.
   PubMed Web of Science ®Google Scholar
• Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 2009;16:631–8.
   PubMed Web of Science ®Google Scholar
• Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15:893–908.
   PubMed Web of Science ®Google Scholar
• Lawson VH, Arnold WD. Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment. Neuropsychiatr Dis Treat 2014;10:567–76.
   PubMed Web of Science ®Google Scholar
• Katz U, Shoenfeld Y, Zandman-Goddard G. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases. Curr Pharm Des 2011;17:3166–75.
   PubMed Web of Science ®Google Scholar
• Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007;6:257–9.
   PubMed Web of Science ®Google Scholar
• Marie I, Maurey G, Herve F, et al. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006;155:714–21.
   PubMed Web of Science ®Google Scholar
• O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2011;39:S1–34.
   PubMed Web of Science ®Google Scholar
• Schleinitz N, Jean E, Benarous L, et al. Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis? Clin Rheumatol 2008;27:1067–8.
   PubMed Web of Science ®Google Scholar
• Haddad E, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci 2012;46:315–21.
   PubMed Web of Science ®Google Scholar
• Cleary LC, Crofford LJ, Long D, et al. Does computed tomography-based muscle density predict muscle function and health-related quality of life in patients with idiopathic inflammatory myopathies? Arthritis Care Res (Hoboken) 2015;67:1031–40.
   PubMed Web of Science ®Google Scholar
• Sadjadi R, Rose MR. What determines quality of life in inclusion body myositis? J Neurol Neurosurg Psychiatry 2010;81:1164–6.
   PubMed Web of Science ®Google Scholar
• Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337–45.
   PubMedGoogle Scholar
• van Schaik IN, Bouche P, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 2006;13:802–8.
   PubMed Web of Science ®Google Scholar
• Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care 1992;30:473–83.
   PubMed Web of Science ®Google Scholar
• Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol 2012;32:1180–92.
   PubMed Web of Science ®Google Scholar
• Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004;114:936–42.
   PubMed Web of Science ®Google Scholar
• Hoffmann F, Grimbacher B, Thiel J, et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res 2010;15:238–45.
   PubMed Web of Science ®Google Scholar
• Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics 2012;6:277–87.
   PubMedGoogle Scholar
• Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag 2010;6:1–10.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Azzari C, Milito C, et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig 2015;35:179–85.
   PubMed Web of Science ®Google Scholar
• Cocito D, Merola A, Peci E, et al. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. J Neurol 2014;261:2159–64.
   PubMed Web of Science ®Google Scholar
• Misbah SA, Baumann A, Fazio R, et al. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 2011;16:92–7.
   PubMed Web of Science ®Google Scholar
• Braine ME, Woodall A. A comparison between intravenous and subcutmaneous immunogobulin. Br J Nurs 2012;21:S21–2, S4–7.
   Google Scholar
• Danieli MG, Pettinari L, Moretti R, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011;10:144–9.
   PubMed Web of Science ®Google Scholar
• Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies – a prospective, multi-national study. J Clin Immunol 2006;26:177–85.
   PubMed Web of Science ®Google Scholar
• Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265–73.
   PubMed Web of Science ®Google Scholar
• Sundin U, Nava S, Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998;112:341–6.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313:670–3.
   PubMed Web of Science ®Google Scholar
• Weiler CR. Immunoglobulin therapy: history, indications, and routes of administration. Int J Dermatol 2004;43:163–6.
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747–55.
   PubMed Web of Science ®Google Scholar
• Robert P. Global plasma demand in 2015. Pharmaceuticals Policy and Law 2009;11:359–67.
   Google Scholar